Literature DB >> 29442900

Doxorubicin Loaded Silica Nanoparticles with Dual Modification as a Tumor-Targeted Drug Delivery System for Colon Cancer Therapy.

Yong-Quan Lin1, Jing Zhang2, Shi-Jiang Liu3, Hui Ye4.   

Abstract

In the following study, we describe the preparation and characterization of poly(ethylene glycol) (PEG) and biotin modified, doxorubicin (DOX) loaded silica nanoparticles (Dox/SLN-PEG-Biotin), which was employed as a drug delivery system for colon cancer therapy. The DOX/SLN-PEG-Biotin exhibited small particle size and low cytotoxicity in vitro. Moreover, the Dox releases from DOX/SLN-PEG-Biotin followed a redox-sensitive behavior. Biotin functionalized Dox/SLN-PEG-Biotin demonstrated tumor-targeted delivery of their payload, resulting in enhanced cellular uptake in HCT116 tumor cells and potentiated tumor accumulation in HCT116 tumor-bearing mice. In particular, in vivo anti-cancer assay confirmed that DOX/SLN-PEG-Biotin as a tumor-targeted delivery system exerted strong anti-cancer efficacy. Altogether, DOX chemotherapy using DOX/SLN-PEG-Biotin might be an effective strategy for improved treatment in colon cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29442900     DOI: 10.1166/jnn.2018.14391

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  2 in total

1.  A novel dual-prodrug carried by cyclodextrin inclusion complex for the targeting treatment of colon cancer.

Authors:  Lin Chen; Yan Lin; Zijun Zhang; Ruisheng Yang; Xiaosheng Bai; Zhongbing Liu; Zhongling Luo; Meiling Zhou; Zhirong Zhong
Journal:  J Nanobiotechnology       Date:  2021-10-19       Impact factor: 10.435

Review 2.  Nanotechnology-Based Strategies to Develop New Anticancer Therapies.

Authors:  Massimiliano Magro; Andrea Venerando; Alberto Macone; Gianluca Canettieri; Enzo Agostinelli; Fabio Vianello
Journal:  Biomolecules       Date:  2020-05-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.